Characteristics and Treatment Experiences of Individuals Using Injectable Semaglutide for Weight Management, a Cross-sectional Time-series Analysis, Multi-country Study.
The purpose of this study is to collect information for scientific research and to better understand the experiences of participants managing their weight. The study aims to collect valid responses through online interviews from participants. This study is a survey-based study without collection of laboratory data. Duration of the study will be about 14 months.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* For an eligible participant (individuals initiated on injectable semaglutide for weight management), all inclusion criteria must be answered "yes".
1. Electronically provided consent obtained before any study-related activities can be completed.
2. Age above or equal to 18 years at the time of providing informed consent.
3. Reside in a participating country: Australia, Germany, United Arab Emirates (UAE) and Spain.
4. Have been prescribed and initiated injectable semaglutide for weight management prior to study screening.
* For an eligible participant (HCPs), all inclusion criteria must be answered "yes".
1. Electronically provided consent obtained before any study-related activities can be completed.
2. Practice in a participating country: Australia, Germany, UAE, and Spain.
3. See at least 150 patients for any condition per month; priority given to those who treat at least 200 patients for any condition per month.
4. Treat at least 10 adult patients per month for weight management.
5. Prescribe anti-obesity medications (AOMs) to their patients they personally treat for weight management/obesity care; priority given to those who treat at least 10% of the patients they personally treat for weight management/obesity care with anti-obesity medications (AOMs).
6. Prescribe injectable semaglutide for weight management.
7. Be a specialty of interest (varies by country); mix of primary care, specialists such as Endocrinologists, Diabetologists, Nutrition Specialists, Obesity Specialists and others.
Exclusion Criteria:
* For an eligible participant (individuals initiated on injectable semaglutide for weight management), all exclusion criteria must be answered "no".
1. Unwillingness or language barriers precluding adequate understanding or cooperation.
2. Is currently or planning to become pregnant in next six months.
3. Is taking injectable semaglutide for Type 2 diabetes management only.
* For an eligible participant (HCPs), all exclusion criteria must be answered "no".
1. Prior participation in this study. Participation is defined as having given informed consent and submitting responses to an interview.
2. Unwillingness or language barriers precluding adequate understanding or cooperation.
3. Only treats patients under 18 years of age.
Primary outcome measure(s)
Description of characteristics, including clinical, demographic and physical characteristics, among individuals initiated on injectable semaglutide for weight management — At the time of survey response (Day 1) Patient Quantitative Segment Multi select from a defined list Single select from a defined list Numeric entry Open-ended type-in Patient Qualitative Segment Open-ended commentary
Description of the experience of individuals initiated on injectable semaglutide for weight management through personal perception of physical and mental health and self-reported QoL — At the time of survey response (Day 1) Patient Quantitative Segment 7-point Likert scale for agreement (where 1 indicates extremely dissatisfied and 7 indicates extremely satisfied) Single select from a defined list EQ-5D-5L Patient Qualitative Segment Open-ended commentary
Individual-reported change in BMI since initiation — At the time of survey response (Day 1) Patient Quantitative Segment Numeric entry (BMI calculated based on self-reported height and weight)
Individual-reported achievement of weight loss goal — At the time of survey response (Day 1) Patient Quantitative Segment Yes/No; percentage of weight loss goal achieved Patient Qualitative Segment Open-ended commentary
Individual-reported change in weight since initiation — At the time of survey response (Day 1) Patient Quantitative Segment Numeric entry in (kgs); percentage of weight change Patient Qualitative Segment Open-ended commentary
Individual-reported changes in daily life since initiation on injectable semaglutide — At the time of survey response (Day 1) Patient Qualitative Segment Open-ended commentary
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.